Ornidazole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ornidazole
Accession Number
DB13026
Description

Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 219.63
Monoisotopic: 219.0410689
Chemical Formula
C7H10ClN3O3
Synonyms
  • ornidazol

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Ornidazole.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Ornidazole.
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Ornidazole.
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Ornidazole.
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Ornidazole.
Gallamine triethiodideThe therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Ornidazole.
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Ornidazole.
Metocurine iodideThe therapeutic efficacy of Metocurine iodide can be increased when used in combination with Ornidazole.
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Ornidazole.
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Ornidazole.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
G01AF06 — OrnidazoleJ01RA09 — Ofloxacin and ornidazoleJ01XD03 — OrnidazoleP01AB03 — OrnidazoleJ01RA05 — Levofloxacin and ornidazoleJ01RA12 — Ciprofloxacin and ornidazole
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Nitroimidazoles
Alternative Parents
1,2,5-trisubstituted imidazoles / Nitroaromatic compounds / N-substituted imidazoles / Heteroaromatic compounds / Secondary alcohols / Chlorohydrins / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organic oxoazanium compounds / Organic oxides
show 6 more
Substituents
1,2,5-trisubstituted-imidazole / Alcohol / Alkyl chloride / Alkyl halide / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Chlorohydrin / Halohydrin
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, secondary alcohol, imidazoles, organochlorine compound (CHEBI:75176)

Chemical Identifiers

UNII
62XCK0G93T
CAS number
16773-42-5
InChI Key
IPWKIXLWTCNBKN-UHFFFAOYSA-N
InChI
InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
IUPAC Name
1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
SMILES
CC1=NC=C(N1CC(O)CCl)N(=O)=O

References

General References
  1. TITCK Product Information: Bitazol (ornidazole) solution for infusion [Link]
  2. TITCK Product Information: Bitazol (ornidazole) film-coated tablets [Link]
  3. TITCK Product Information: Bitazol (ornidazole) vaginal tablets [Link]
  4. TITCK Product Information: Ornisasin (ornidazole/ciprofloxacin hydrochloride) film-coated tablets [Link]
PubChem Compound
28061
PubChem Substance
347829160
ChemSpider
26102
RxNav
7701
ChEBI
75176
ChEMBL
CHEMBL1449676
Wikipedia
Ornidazole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionElective Colorectal Surgery1
3RecruitingPreventionMalignant Neoplasm of Colon1
3RecruitingPreventionRectal Cancer Surgery1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coated500 mg
Tablet, film coated250 mg
SuppositoryVaginal500 mg
Injection, solutionIntravenous500 mg
Tablet, coated250 mg
Tablet, coated500 mg
SolutionIntravenous500 mg/3ml
SolutionParenteral500 mg/3ml
Tablet, film coatedOral500 mg
Injection, solutionIntravenous500 mg/3ml
InjectionIntravenous500 mg/3ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.34 mg/mLALOGPS
logP0.37ALOGPS
logP0.26ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)3.08ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.87 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity50.23 m3·mol-1ChemAxon
Polarizability19.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-0590000000-51e17e00bdee7b7e70f6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-1590000000-10d4a11d06fa5ff22012
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-3911000000-5b4872e026a447ba42bd

Drug created on October 20, 2016 20:10 / Updated on October 22, 2020 14:10

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates